Tenon Medical Reports Strong Preliminary Q4 and Full Year 2025 Revenue Growth
Summary
Tenon Medical, Inc. announced preliminary unaudited revenue for Q4 2025 of $1.45M-$1.48M, representing 90% year-over-year growth, and full-year 2025 revenue of $3.91M-$3.94M, up 20% year-over-year.
Key Events
-
Strong Preliminary Q4 2025 Revenue
The company reported unaudited revenue for the fourth quarter of 2025 totaling $1.45 million to $1.48 million, marking an approximate 90% increase year-over-year.
-
Solid Preliminary Full Year 2025 Revenue
Unaudited revenue for the full 2025 fiscal year reached $3.91 million to $3.94 million, representing an approximate 20% increase compared to 2024.
-
Upcoming Full Earnings Release
Tenon Medical plans to release its full financial results for Q4 and FY 2025 after market close on Thursday, March 19, 2026, followed by a conference call.
Analysis
Tenon Medical, a micro-cap company, announced robust preliminary revenue figures for the fourth quarter and full year 2025. The reported Q4 revenue of $1.45M to $1.48M represents an impressive approximately 90% year-over-year increase, while full-year revenue of $3.91M to $3.94M shows approximately 20% growth. For a company of this size, these growth rates and revenue figures are highly significant, indicating strong operational momentum. This positive news, especially while the stock is trading near its 52-week low, could serve as a substantial catalyst for investor sentiment and potentially re-rate the stock.
At the time of this filing, TNON was trading at $0.67 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $7.5M. The 52-week trading range was $0.64 to $5.85. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.